FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Dynavax Technologies Corporation Stock AnalysisComprehensive stock analysis for Dynavax Technologies Corporation (DVAX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDVAX
DVAX
Dynavax Technologies Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DVAX
Home🔹Stocks🔹Dynavax Technologies Corporation

Dynavax Technologies Corporation

DVAX•NASDAQ

Dynavax Technologies Corporation

DVAX•NASDAQ
Market cap
$1.82B
Sentiment

Your view on DVAX

Mkt Cap
$1.82B
Sentiment
Your view
DVAX
Dynavax Technologies Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DVAX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Dynavax Technologies Corporation

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Ryan Spencer
Headquarters
2100 Powell Street, EmeryVille, CA, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Ryan Spencer
Headquarters
2100 Powell Street, EmeryVille, CA, US
Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News